INDICATION

Aptensio XR® (methylphenidate HCl extended-release) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

For US Healthcare Professionals

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including Aptensio XR, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

.

PRODUCT DESIGN

Each extended-release capsule of Aptensio XR is designed to have a 12-hour duration of effect1

.

Aptensio XR can be taken before school, work, or other start-of-morning activities1

  • Aptensio XR® (methylphenidate HCl extended-release) demonstrated statistical significance at all time points tested post dose: 1, 2, 3, 4.5, 6, 7.5, 9, 10.5, and 12 hours1
Aptensio Product Design

Patented multilayer-release bead design in each capsule1

  • Aptensio XR delivers ~40% of methylphenidate as immediate-release and ~60% as extended-release that is delayed for later in the patient’s day1
.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including Aptensio XR, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.